ARID1A expression in gastric adenocarcinoma: Clinicopathological significance and correlation with DNA mismatch repair status

Table 3 Clinicopathological features of 489 patients with gastric cancer according to ARID1A expression n (%)

	ARID1A expression		P value
	Loss/weak(n = 109)	Retained(n = 380)
Age (yr)			0.2121
mean ± SD	62.1 ± 10.9	60.7 ± 12.0
Gender			0.4192
Male	69 (63.3)	258 (67.9)
Female	40 (36.7)	122 (32.1)
Serum CEA (ng/mL)			0.9371
mean ± SD	39.7 ± 363.4	35.3 ± 301.3
Tumor size (mm)			0.3361
mean ± SD	83.9 ± 46.1	79.2 ± 44.8
Tumor location			0.0672
Fundus and Corpus	87 (79.8)	269 (70.8)
Antrum	22 (20.2)	111 (29.2)
Histology			0.7392
Differentiated type	41 (37.6)	152 (40.0)
Undifferentiated type	68 (62.4)	228 (60.0)
Lymphatic invasion			0.0222
Absent	21 (19.3)	116 (30.5)
Present	88 (80.7)	264 (69.5)
Venous invasion			0.4432
Absent	59 (54.1)	222 (58.4)
Present	50 (45.9)	158 (41.6)
Primary tumor			0.0652
T2, 3	45 (41.3)	184 (48.4)
T4	64 (58.7)	196 (51.6)
Lymph node involvement			0.0422
N0	18 (16.5)	100 (26.3)
N1, 2, 3	91 (83.5)	280 (73.7)
Distant metastasis			0.7252
M0	73 (67.0)	263 (69.2)
M1	36 (33.0)	117 (30.8)
Stage			0.1112
Stage I, II	31 (28.4)	141 (37.1)
Stage III, IV	78 (71.6)	239 (62.9)
Residual disease			0.7982
Negative	85 (78.0)	290 (76.3)
Positive	24 (22.0)	90 (23.7)

¹Mann-Whitney U test;

²Fisher’s exact test. CEA: Carcinoembryonic antigen.